FDA: Advisory panel backs COVID-19 boosters only for 65+, those at high risk
The decision was made by a committee of outside experts who advise the Food and Drug Administration.
Share:
More Stories
1:54
Boar’s Head deli meat recalled for potential listeria contamination
27m ago1:37
Storm Watch Team Meteorologist Skyler Harman strikes down lightning myths
3h ago1:40
Nearly 300 probationary firefighters join the ranks of FDNY
4h ago1:47
Volunteers come together to clean up local green space, call on NYC officials for more cleaning efforts
4h ago0:57
Hundreds of Bronx residents pick up fresh food at Morrisania food pantry
5h ago1:48
NYPD: 2 women wanted for assaulting, robbing woman at bodega on Grand Concourse
5h ago1:54
Boar’s Head deli meat recalled for potential listeria contamination
27m ago1:37
Storm Watch Team Meteorologist Skyler Harman strikes down lightning myths
3h ago1:40
Nearly 300 probationary firefighters join the ranks of FDNY
4h ago1:47
Volunteers come together to clean up local green space, call on NYC officials for more cleaning efforts
4h ago0:57
Hundreds of Bronx residents pick up fresh food at Morrisania food pantry
5h ago1:48
NYPD: 2 women wanted for assaulting, robbing woman at bodega on Grand Concourse
5h agoAn influential federal advisory panel has overwhelmingly rejected a plan to give Pfizer booster shots against COVID-19 to most Americans, but it endorsed the extra shots for those who are 65 or older or run a high risk of severe disease.
The twin votes Friday represented a heavy blow to the Biden administration's sweeping effort to shore up nearly all Americans' protection amid the spread of the highly contagious delta variant.
The decision was made by a committee of outside experts who advise the Food and Drug Administration.
The twin votes Friday represented a heavy blow to the Biden administration's sweeping effort to shore up nearly all Americans' protection amid the spread of the highly contagious delta variant.
The decision was made by a committee of outside experts who advise the Food and Drug Administration.
Editor's note: An earlier version of this story misstated the Pfizer vote count as 61-3, it was 16-2.
